Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

NCT04476459 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Follicular Lymphoma Grade IIIb
Transformed Lymphoma
EBV-Positive DLBCL, Nos
ALK-Positive Anaplastic Large Cell Lymphoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Huiqiang Huang